biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > If Prothena's PRX012 is an xB3 drug, then...

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon May 04, 2023 2:58pm

92 Views

Post# 35430831

RE:If Prothena's PRX012 is an xB3 drug, then...

If Prothena's PRX012 is an xB3 drug, then because Alzheimer's is a chronic disease that will likely require lifetime treatments, then we'll learn whether potential prolonged off-target delivery of an xB3 drug to LRP-1 receptors in the CNS might be a problem or not. That might dispel concerns, if they exist, that using that receptor is problematic as suggested by the piece I wrote about that in late 2020.

jd.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale